View Future GrowthHLB Genex 과거 순이익 실적과거 기준 점검 3/6HLB Genex은 연평균 37.3%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 0.3% 증가했습니다. 매출은 연평균 14.7%의 비율로 증가했습니다. HLB Genex의 자기자본이익률은 40.6%이고 순이익률은 48.3%입니다.핵심 정보37.27%순이익 성장률35.85%주당순이익(EPS) 성장률Chemicals 산업 성장률13.95%매출 성장률14.66%자기자본이익률40.61%순이익률48.29%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트분석 기사 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.모든 업데이트 보기Recent updates분석 기사 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,175, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.공시 • Mar 17HLB Genex, Inc., Annual General Meeting, Mar 30, 2026HLB Genex, Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, techno3-ro, yuseong-gu, daejeon South Korea분석 기사 • Feb 02These 4 Measures Indicate That HLB Genex (KOSDAQ:187420) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...공시 • May 22HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion.HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion on May 21, 2025. A cash consideration of KRW 8.17 billion will be paid by HLB Genex, Inc. for 1,078,841 shares. Upon completion, HLB Genex, Inc. will own 57.83% stake in GF Fermentech Co., Ltd. For the period ending December 31, 2024, GF Fermentech Co., Ltd. reported total revenue of KRW 19.03 billion and net income of KRW 4.05 billion. As of December 31, 2024, GF Fermentech Co., Ltd. reported total debt of KRW 18.27 billion, total assets of KRW 40.35 billion and total common equity of KRW 22.08 billion. The expected completion of the transaction is May 26, 2025.New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩103.4b market cap, or US$70.3m).New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩98.2b market cap, or US$67.2m).공시 • Mar 14HLB Genex, Inc., Annual General Meeting, Mar 28, 2025HLB Genex, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 75, techno1-ro, yuseong-gu, daejeon South Korea공시 • Dec 13GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investorsOn December 12, 2024 GenoFocus, Inc. closed the transaction.공시 • Oct 30GenoFocus, Inc. announced that it expects to receive KRW 55 billion in fundingGenoFocus, Inc. announced a private placement to issue Series 5 Bearer unsecured private placement convertible bonds for a gross proceeds of KRW 55,000,000,000 on October 28, 2024. The bonds a coupon rate of 1% and yield to maturity of 2%. The bonds will mature on December 12, 2027. The bonds will be 100% converted into 17,851,346 common shares at a fixed conversion price of KRW 3,081 per share. The conversion period is from December 12, 2025 to November 12, 2027. The payment date of the transaction is December 12, 2024. The transaction has been approved by the board of directors of the company. The transaction includes participation from Nomad No. 5 Fund for KRW 42,500,000,000, Armart New Technology Fund No. 304 for KRW 9,000,000,000, Lim Jihyun for KRW 3,000,000,000 and The Global Asset Management, Inc. for KRW 500,000,000.분석 기사 • Oct 29There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price JumpGenoFocus, Inc. ( KOSDAQ:187420 ) shares have had a really impressive month, gaining 30% after a shaky period...공시 • Oct 04Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion.Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion on September 30, 2024. For the period ending December 31, 2023, GF Fermentech Co., Ltd. reported total revenue of KRW 13.88 billion and net income of KRW 10.13 billion, total debt of KRW 34.35 billion, total assets of KRW 52.41 billion and total common equity of KRW 18.06 billion. The expected completion of the transaction is October 4, 2024.분석 기사 • Aug 05GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Aug 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩81.3b market cap, or US$60.0m).분석 기사 • Apr 13Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 24New 90-day low: ₩7,700The company is down 20% from its price of ₩9,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.분석 기사 • Feb 16Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?It hasn't been the best quarter for GenoFocus, Inc. ( KOSDAQ:187420 ) shareholders, since the share price has fallen...Is New 90 Day High Low • Jan 18New 90-day low: ₩8,800The company is down 37% from its price of ₩14,000 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period.분석 기사 • Dec 22Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Sep 23New 90-day high: ₩16,900The company is up 186% from its price of ₩5,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.공시 • Aug 30GenoFocus, Inc. announced that it has received KRW 10 billion in fundingOn August 24, 2020, GenoFocus, Inc. (KOSDAQ:A187420) closed the transaction.공시 • Aug 22GenoFocus, Inc. announced that it expects to receive KRW 10 billion in fundingGenoFocus, Inc. (KOSDAQ:A187420) announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on August 21, 2020. The transaction will include participation from K2 Expedio Fund. The bonds carry a Surface interest rate 0% and interest rate to maturity of 3%. The bonds will mature on August 24, 2025. The bonds can be 100% converted into 1,470,804 common shares for 6.65% stake of the company at a fixed conversion price of KRW 6,799 per share. The conversion period is from August 24, 2021 to July 24, 2025. . The transaction is expected to close by August 24, 2020. The transaction has been approved by the board of directors of the company.매출 및 비용 세부 내역HLB Genex가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A187420 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2644,34621,4147,6435,98031 Dec 2543,37022,5917,2185,90330 Sep 2540,950-3,2676,4907,93630 Jun 2539,914-886,0638,28931 Mar 2539,009-18,5675,6439,66531 Dec 2435,430-18,8285,34310,27130 Sep 2434,8341,0452,3708,92930 Jun 2432,197-2,8563,91111,02131 Mar 2428,048-1,4443,84110,99731 Dec 2327,008-2,9504,02511,60830 Sep 2325,340-15,8795,88213,05030 Jun 2325,467-13,6684,35611,89131 Mar 2327,827-13,7064,47612,14731 Dec 2227,802-12,9684,23011,68130 Sep 2227,274-8,8374,18311,54130 Jun 2227,140-8,6413,71611,45731 Mar 2226,427-8,2223,36011,57031 Dec 2125,874-6,8172,91310,41330 Sep 2122,921-10,3122,82810,37030 Jun 2120,533-10,2982,5679,81031 Mar 2119,258-13,0352,4518,27431 Dec 2018,769-12,2172,3648,02530 Sep 2018,853-5,1422,2905,92230 Jun 2017,807-5,7292,1815,14931 Mar 2016,287-5,9072,1894,98331 Dec 1914,942-5,7592,1514,26130 Sep 1912,878-5,9521,9753,40130 Jun 1913,169-3,4271,9282,14431 Mar 1912,388-3,0201,7671,20231 Dec 1811,518-2,3231,80889930 Sep 1811,592-431,64967130 Jun 1811,1384331,64553731 Mar 1811,6851,4571,77235931 Dec 1711,5061,4111,59435230 Sep 1710,9222,0441,58929530 Jun 179,8952,2141,53236031 Mar 178,0542,1231,30233131 Dec 167,0291,6151,26526530 Sep 166,5628741,18824730 Jun 166,4611,2431,14612431 Mar 166,6541,1871,07110831 Dec 156,6401,21197813630 Sep 158,4103,19291020330 Jun 157,7962,569858208양질의 수익: A187420의 비현금 수익 수준이 높습니다.이익 마진 증가: A187420는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A187420는 지난 5년 동안 흑자전환하며 연평균 37.3%의 수익 성장을 기록했습니다.성장 가속화: A187420는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: A187420는 지난해 흑자전환하여 지난 해 수익 성장률을 Chemicals 업계(-3.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A187420의 자본 수익률(40.6%)은 뛰어남으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/31 01:53종가2026/05/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스HLB Genex, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
분석 기사 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...
Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
분석 기사 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,175, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.
공시 • Mar 17HLB Genex, Inc., Annual General Meeting, Mar 30, 2026HLB Genex, Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, techno3-ro, yuseong-gu, daejeon South Korea
분석 기사 • Feb 02These 4 Measures Indicate That HLB Genex (KOSDAQ:187420) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
공시 • May 22HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion.HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion on May 21, 2025. A cash consideration of KRW 8.17 billion will be paid by HLB Genex, Inc. for 1,078,841 shares. Upon completion, HLB Genex, Inc. will own 57.83% stake in GF Fermentech Co., Ltd. For the period ending December 31, 2024, GF Fermentech Co., Ltd. reported total revenue of KRW 19.03 billion and net income of KRW 4.05 billion. As of December 31, 2024, GF Fermentech Co., Ltd. reported total debt of KRW 18.27 billion, total assets of KRW 40.35 billion and total common equity of KRW 22.08 billion. The expected completion of the transaction is May 26, 2025.
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩103.4b market cap, or US$70.3m).
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩98.2b market cap, or US$67.2m).
공시 • Mar 14HLB Genex, Inc., Annual General Meeting, Mar 28, 2025HLB Genex, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 75, techno1-ro, yuseong-gu, daejeon South Korea
공시 • Dec 13GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investorsOn December 12, 2024 GenoFocus, Inc. closed the transaction.
공시 • Oct 30GenoFocus, Inc. announced that it expects to receive KRW 55 billion in fundingGenoFocus, Inc. announced a private placement to issue Series 5 Bearer unsecured private placement convertible bonds for a gross proceeds of KRW 55,000,000,000 on October 28, 2024. The bonds a coupon rate of 1% and yield to maturity of 2%. The bonds will mature on December 12, 2027. The bonds will be 100% converted into 17,851,346 common shares at a fixed conversion price of KRW 3,081 per share. The conversion period is from December 12, 2025 to November 12, 2027. The payment date of the transaction is December 12, 2024. The transaction has been approved by the board of directors of the company. The transaction includes participation from Nomad No. 5 Fund for KRW 42,500,000,000, Armart New Technology Fund No. 304 for KRW 9,000,000,000, Lim Jihyun for KRW 3,000,000,000 and The Global Asset Management, Inc. for KRW 500,000,000.
분석 기사 • Oct 29There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price JumpGenoFocus, Inc. ( KOSDAQ:187420 ) shares have had a really impressive month, gaining 30% after a shaky period...
공시 • Oct 04Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion.Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion on September 30, 2024. For the period ending December 31, 2023, GF Fermentech Co., Ltd. reported total revenue of KRW 13.88 billion and net income of KRW 10.13 billion, total debt of KRW 34.35 billion, total assets of KRW 52.41 billion and total common equity of KRW 18.06 billion. The expected completion of the transaction is October 4, 2024.
분석 기사 • Aug 05GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Aug 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩81.3b market cap, or US$60.0m).
분석 기사 • Apr 13Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 24New 90-day low: ₩7,700The company is down 20% from its price of ₩9,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
분석 기사 • Feb 16Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?It hasn't been the best quarter for GenoFocus, Inc. ( KOSDAQ:187420 ) shareholders, since the share price has fallen...
Is New 90 Day High Low • Jan 18New 90-day low: ₩8,800The company is down 37% from its price of ₩14,000 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period.
분석 기사 • Dec 22Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Sep 23New 90-day high: ₩16,900The company is up 186% from its price of ₩5,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.
공시 • Aug 30GenoFocus, Inc. announced that it has received KRW 10 billion in fundingOn August 24, 2020, GenoFocus, Inc. (KOSDAQ:A187420) closed the transaction.
공시 • Aug 22GenoFocus, Inc. announced that it expects to receive KRW 10 billion in fundingGenoFocus, Inc. (KOSDAQ:A187420) announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on August 21, 2020. The transaction will include participation from K2 Expedio Fund. The bonds carry a Surface interest rate 0% and interest rate to maturity of 3%. The bonds will mature on August 24, 2025. The bonds can be 100% converted into 1,470,804 common shares for 6.65% stake of the company at a fixed conversion price of KRW 6,799 per share. The conversion period is from August 24, 2021 to July 24, 2025. . The transaction is expected to close by August 24, 2020. The transaction has been approved by the board of directors of the company.